Best Formulations is a leading CDMO provider of contract R&D and production of nutritional supplement products in the United States. It has the ability to produce a variety of dosage forms and develop complex formulations in the field of soft capsule products, and has begun to deploy gummies and personal care products. Xianle Health (300791) announced on the evening of July 7 that it intends to acquire an 80% stake in Best Formulations. The acquisition of the shares requires payment of a transaction consideration of approximately US$180 million, or approximately RMB 1.211 billion.
This article is reprinted from: https://www.itjuzi.com/merger/9073
This site is for inclusion only, and the copyright belongs to the original author.